HC Wainwright Analysts Decrease Earnings Estimates for CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Capricor Therapeutics in a research report issued to clients and investors on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($0.61) per share for the quarter, down from their prior estimate of ($0.60). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.43) EPS and FY2027 earnings at ($2.57) EPS.

A number of other equities research analysts also recently weighed in on the company. B. Riley Financial lifted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a research note on Friday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $48.36.

Capricor Therapeutics Stock Down 1.7%

NASDAQ:CAPR opened at $29.81 on Friday. The firm has a market capitalization of $1.72 billion, a PE ratio of -12.85 and a beta of 0.48. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37. The firm has a 50-day moving average price of $31.79 and a 200 day moving average price of $24.20.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04).

Insider Transactions at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the sale, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. This represents a 75.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karimah Es Sabar sold 61,265 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 172,529 shares of company stock worth $5,302,440. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of Capricor Therapeutics in the third quarter valued at about $1,555,000. Moody Aldrich Partners LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $6,025,000. Pier Capital LLC lifted its position in shares of Capricor Therapeutics by 35.0% during the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after purchasing an additional 128,837 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Capricor Therapeutics by 396.2% during the third quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 23,974 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.